A Message From Koehnk:
I am a Veterinarian and the CEO of Vicinius Bio, INC. Veterinarians are uniquely qualified to lead human health companies due to our broad education, the connected nature of humans and animals with regards to both infectious and non-infectious disease, and the necessary emphasis on business ownership and entrepreneurialism that is critical to success within the field. Veterinarians are expected to be business owners at some point in their career. My formal education included not only classes in Veterinary Medicine, but also basic business classes and electives in entrepreneurialism. During my education, I also partnered with a classmate to create Premium Animal Research, Inc., an S-Corp from which performed contract animal field research while studying Veterinary Medicine full-time. I credit this opportunity to the entrepreneurial spirit and training I received in my education.
Veterinarians have also been shown to be strong leaders in human pharma. The most notable current example s Dr. Albert Bourla, DVM, the current CEO and Chair of the Board of Directors at Pfizer,the second largest pharmaceutical company in the United States. Dr. Bourla successfully led Pfizer through the unprecedented COVID pandemic and continues to serve as the company’s CEO to this day. Another notable example is Dr. Pascal Soriot, DVM, the CEO of Astra Zeneca since 1981.
While pandemics and epidemics are a relatively rare occurrence in human health, they are a yearly occurrence in veterinary medicine. At the same time, the emphasis for the decrease in the use of antibiotics in domestic species has put an increased emphasis on vaccination technology. For this reason, experience with a variety of vaccines and platforms is extremely robust within the veterinary field.
My involvement in vaccine R&D, licensing, manufacturing, and post-marketing support spans over 20 years. My work includes development and/or licensing and manufacturing of live and inactivated vaccines for the prevention of diseases including those attributed to E. coli, Salmonella, Erysipelas, Clostridium perfringens, Clostridium septicum, Adenovirus, Paramyxovirus, Circovirus, Influenza virus, Reovirus, Parvovirus, Betaarterivirus, rabies virus, Baculovirus construct recombinant platforms, and Poxvirus recombinant platforms. Ongoing and recently completed projects that I am working on are of a proprietary nature due to the commercial aspect of my work. Overall, my broad-based experience, including the development of vaccines, makes me uniquely qualified to lead this SBIR project.
Due to the nature of my work as an owner, my honors have been primarily recognized by the market in the successful development and licensing of vaccines for sale in both the United States and abroad. In essence, the market has shown my scientific work to be valuable through the regulatory approval and sale of effective products.
Citations:
Campbell, Joy & Russell, L. & Crenshaw, Joe & Koehnk, Hans. (2006). Effect of Spray-Dried Plasma Form and Duration of Feeding on Broiler Performance During Natural Necrotic Enteritis Exposure. The Journal of Applied Poultry Research. 15. 584-591. 10.1093/japr/15.4.584.
Positions, Scientific Appointments, and Honors:
Positions and Scientific Appointment
1994-1996 — Laboratory Coordinator for the Edward Brown Laboratory, University of Northern Iowa
1998-2001 — Owner, Premium Animal Research
2000-2001 — Associate Veterinarian, Flying Cloud Animal Hospital, Eden Prairie, Minnesota
2001-Present — Owner, Director of Research and Development ARKO Laboratories, LTD
2022-Present — CEO, Vicinius Bio Inc.
Honors:
1999 — John Poppajohn Entrepreneurial Scholarship Winner, Iowa State University
2007-2011 — Delegate to the American Veterinary Medical Association
2012-2016 — Vice President, President-Elect, President, Immediate Past President: Iowa Veterinary Medical Association
Contributions to Science:
Braddock, J., Richter, Z., “Microbiology of Subtidal Sediments: Monitoring Microbial Populations” Exxon Valdez Oil Spill Restoration Project, Final Report 93047-2; June 1994. www.arlis.org/docs/vol1/33964083.pdf
Web Design and Development by Saltech Systems